🔗 Share this article Individuals Discontinuing Weight-Loss Injections Gain Back Weight Far More Rapidly Compared to Dieters Weight management often requires ongoing approaches. A recent study reveals that patients who stop using new weight-loss injections like semaglutide or tirzepatide can put back on lost weight at a significantly accelerated pace than those who stop traditional lifestyle regimens. Published data in a prominent medical journal demonstrates that while overweight individuals often shed a large proportion of their body weight while on the medication, the mass returns at an estimated rate of nearly a kilo each month once they quit. "People using these treatments must be informed of the risk of fast rebound weight gain when the therapy is stopped," cautioned researcher Dr. Susan Jebb. Such speed of recovery implies a reversion to original weight in about a year and a half. Weighing Treatments The analysis, which reviewed dozens of trials involving thousands of participants, contrasted the effects of the injectable medications with older methods. Scientists emphasize that individuals who shed pounds through diet and exercise typically see a slower weight regain—around 100 grams monthly—after stopping. Explaining the Fast Rebound Doctors believe the way of the injections is key to understanding the amplified weight return. These medications imitate a body's own chemical called glucagon-like peptide-1, which controls hunger. "Long-term administration of the hormone concentrations far above than the body's typical production may cause the body to generate a reduced amount of its own natural hormone, and could diminish sensitivity to its effects," noted Dr. Adam Collins, a dietetics specialist. "Stopping of this GLP-1 'fix' leads to appetite is unsuppressed, making overeating much more probable." A Lifelong Disease? The NHS recommend the jabs for people with obesity-related health risks, alongside recommended diet and exercise modifications. Many experts argue that, considering the likelihood of weight regain, the treatment should be considered long-term. This opinion is echoed by pharmaceutical companies, who state that the findings "emphasize the long-term nature of excess weight," comparing it to managing diseases like high blood pressure. Patient Experiences Users who have stopped the jabs explain a intense resurgence of hunger. "It was like something activating and you're instantly extremely hungry," described a patient. The struggle is compounded if users have not developed lasting dietary or behavioural changes during therapy. Widespread Interest Survey data show that millions of people in the UK have tried these injections in the last 12 months, with demand remaining high. Use is more common among females than men. The middle-aged demographic shows the greatest level of interest. A large proportion obtain the drugs through private prescriptions rather than the NHS. Finally, experts caution that while the jabs are potent agents for weight loss, they are not a permanent cure and lasting health benefits hinges on ongoing lifestyle support.
Weight management often requires ongoing approaches. A recent study reveals that patients who stop using new weight-loss injections like semaglutide or tirzepatide can put back on lost weight at a significantly accelerated pace than those who stop traditional lifestyle regimens. Published data in a prominent medical journal demonstrates that while overweight individuals often shed a large proportion of their body weight while on the medication, the mass returns at an estimated rate of nearly a kilo each month once they quit. "People using these treatments must be informed of the risk of fast rebound weight gain when the therapy is stopped," cautioned researcher Dr. Susan Jebb. Such speed of recovery implies a reversion to original weight in about a year and a half. Weighing Treatments The analysis, which reviewed dozens of trials involving thousands of participants, contrasted the effects of the injectable medications with older methods. Scientists emphasize that individuals who shed pounds through diet and exercise typically see a slower weight regain—around 100 grams monthly—after stopping. Explaining the Fast Rebound Doctors believe the way of the injections is key to understanding the amplified weight return. These medications imitate a body's own chemical called glucagon-like peptide-1, which controls hunger. "Long-term administration of the hormone concentrations far above than the body's typical production may cause the body to generate a reduced amount of its own natural hormone, and could diminish sensitivity to its effects," noted Dr. Adam Collins, a dietetics specialist. "Stopping of this GLP-1 'fix' leads to appetite is unsuppressed, making overeating much more probable." A Lifelong Disease? The NHS recommend the jabs for people with obesity-related health risks, alongside recommended diet and exercise modifications. Many experts argue that, considering the likelihood of weight regain, the treatment should be considered long-term. This opinion is echoed by pharmaceutical companies, who state that the findings "emphasize the long-term nature of excess weight," comparing it to managing diseases like high blood pressure. Patient Experiences Users who have stopped the jabs explain a intense resurgence of hunger. "It was like something activating and you're instantly extremely hungry," described a patient. The struggle is compounded if users have not developed lasting dietary or behavioural changes during therapy. Widespread Interest Survey data show that millions of people in the UK have tried these injections in the last 12 months, with demand remaining high. Use is more common among females than men. The middle-aged demographic shows the greatest level of interest. A large proportion obtain the drugs through private prescriptions rather than the NHS. Finally, experts caution that while the jabs are potent agents for weight loss, they are not a permanent cure and lasting health benefits hinges on ongoing lifestyle support.